CD38 and Miyoshi myopathy: Indeed, we could demonstrate that ISB 2001 was able to induce killing of tumor cells from the bone marrow of patients with MM at different concentrations, whereas the control molecules lacking either the anti-CD38 or the anti-BCMA binding domain could not.